Authors

By John D. Zoidis, MD, Prachi Patel-Predd

Latest:

News Reports: June 2007

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more

By John Zoidis, MD

Latest:

Five-year Follow-Up of 300 Patients Treated with Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy of CLL

Final results for the complete cohort of 300 patients with chronic lymphocytic leukemia (CLL) receiving the FCR (fludarabine, cyclophosphamide, and rituximab)regimen were presented at this year%u2019s American Society of Clinical Oncology meeting.

By Jonathan Bertman, MD

Latest:

Influential Online Communities

As we begin 2009, I am struck by how radically different the Internet looks and acts today compared to just 10 years ago.

By Jonathan S. Batchelor

Latest:

Amonafide Plus Cytarabine Fails To Meet Primary Endpoint

Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data

By Joseph Burns

Latest:

COME HOME Program Set to Save $33.5M Over 3 Years

In an interview with Oncology Business Management, Barbara L. McAneny, MD, explains how the program will address fragmented care, suboptimal outcomes, high costs, and patient dissatisfaction.

By Julie Beck, RN, MSN, MPH, APRN-BC

Latest:

Nurse-Driven Website Empowers Nurses to Improve Patient Care

Improving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.

By Justin Watts, MD

Latest:

Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a Decade

Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.

By Kadi-Ann Harvey-Bryan, MD

Latest:

Ablative Therapies for Small Renal Masses

A peer-reviewed summary of the ablative techniques currently available for the treatment of small renal masses.

By Keith A. Delman, MD

Latest:

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.

By L. Stewart Massad, MD

By Lary A. Robinson, MD

Latest:

Pancoast Tumors of the Lung: Improved Results

Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.

By Linda M. Goodfellow, PhD, RN

Latest:

Don't Forget the Partner of a Patient With Cancer

Linda Goodfellow, PhD, RN, of Duquesne University, discussing the important role nurses play in supporting the spouses of patients with cancer, a critical, yet often unmet need.

By Marianne Davies, RN, MSN, ACNP, AOCNP

Latest:

Journal Club Bridges Research and Practice, Improving Patient Care

Three oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.

By Marissa Howard-McNatt, MD

Latest:

BRCA Testing and Contralateral Prophylactic Mastectomy

Determination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates suggest that about 80% of breast cancers and 90% of ovarian cancers are sporadic; while only 5% to 10% of breast cancers are hereditary.

By Mark A. Becker, MD

Latest:

Provide Your Patients with an Online Resource You can Both Trust...Your Own!

Patients are going online for health information but would prefer to get it from you. Are you there to help them?

By Mary K. Caffrey

Latest:

Pomalidomide Shows Benefits in Trials Testing New Combinations

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

By Matthew Mahady

Latest:

Flash Findings: Cancer Facts: July 6, 2010

A collection of cancer statistics and facts

By Michael M. Mohundro, PharmD

Latest:

The Future of Melanoma Treatment

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.

By Nadine M. Hasenecz

Latest:

FDA Says Simvastatin & Ezetimibe Unlikely to Cause Cancer

The FDA concludes that the cholesterol-lowering drugs simvastatin (Zocor),ezetimibe (Zetia), and Vytorin (ezetimibe/simvastatin) are not likely to increase cancer risk.

By Nany Tice, MD

Latest:

Get Connected with Online Physician Consultations

How does today's connected, "always on" world translate to your medical practice?